

# Andrew R Rezvani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10851197/publications.pdf>

Version: 2024-02-01

56  
papers

1,652  
citations

394421

19  
h-index

302126

39  
g-index

57  
all docs

57  
docs citations

57  
times ranked

2128  
citing authors

#	ARTICLE	IF	CITATIONS
1	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 109.e1-109.e8.	1.2	12
2	Rare transmission of commensal and pathogenic bacteria in the gut microbiome of hospitalized adults. <i>Nature Communications</i> , 2022, 13, 586.	12.8	21
3	Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 215.e1-215.e10.	1.2	11
4	Impact of conditioning regimen intensity on the outcomes of peripheral Tâ€cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic Tâ€cell lymphoma patients undergoing allogeneic transplant. <i>British Journal of Haematology</i> , 2022, 197, 212-222.	2.5	6
5	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 406.e1-406.e6.	1.2	4
6	Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 286-291.	1.2	10
7	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CARâ€refractory large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2321-2325.	1.4	51
8	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. <i>Blood</i> , 2021, 137, 420-428.	1.4	119
9	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 143-155.	5.2	92
10	Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. <i>Blood</i> , 2021, 138, 1429-1440.	1.4	54
11	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	7.1	44
12	Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 590.e1-590.e8.	1.2	5
13	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	30.7	273
14	A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 932.e1-932.e11.	1.2	18
15	Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 879.e1-879.e3.	1.2	0
16	MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT. <i>Blood</i> , 2021, 138, 2955-2955.	1.4	0
17	Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. <i>Blood</i> , 2021, 138, 3885-3885.	1.4	2
18	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 741-741.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study. <i>Blood</i> , 2021, 138, 98-98.	1.4	2
20	Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101. <i>Blood</i> , 2021, 138, 3956-3956.	1.4	0
21	Costs and Outcomes with Once-Daily versus Every-6-Hour Intravenous Busulfan in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 145-149.	2.0	2
22	Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1811-1818.	2.0	4
23	Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	26
24	Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study. <i>Blood</i> , 2020, 136, 22-23.	1.4	2
25	CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 28-29.	1.4	3
26	Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants. <i>Blood</i> , 2020, 136, 47-48.	1.4	4
27	Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 33-34.	1.4	0
28	Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis. <i>Blood</i> , 2020, 136, 48-49.	1.4	0
29	Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2020, 136, 11-12.	1.4	0
30	Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant. <i>Blood</i> , 2020, 136, 22-23.	1.4	0
31	Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity. <i>Blood</i> , 2020, 136, 32-33.	1.4	4
32	Incidence of Active Tuberculosis After Hematopoietic Cell Transplantation: A Small but Real Threat. <i>Clinical Infectious Diseases</i> , 2019, 70, 1261-1262.	5.8	2
33	Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study. <i>Blood Advances</i> , 2019, 3, 3602-3612.	5.2	24
34	Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. <i>JCI Insight</i> , 2019, 4, .	5.0	46
35	No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial. <i>Blood</i> , 2019, 134, 146-146.	1.4	2
36	Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2019, 134, 2022-2022.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	5.2	27
38	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 117.	17.0	20
39	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	1.4	210
40	HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. <i>Blood Advances</i> , 2017, 1, 1347-1357.	5.2	8
41	Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. <i>Blood</i> , 2016, 128, 2899-2908.	1.4	70
42	Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 4615-4615.	1.4	1
43	Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8026-8026.	1.6	3
44	Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7046-7046.	1.6	0
45	Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors. <i>Blood</i> , 2016, 128, 4669-4669.	1.4	0
46	Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Cancer</i> , 2015, 121, 3709-3716.	4.1	27
47	Long-Term Outcomes of Patients with Persistent Indolent B-Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 281-287.	2.0	19
48	Impact of Donor Age on Outcome after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 105-112.	2.0	47
49	Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. <i>Blood</i> , 2015, 126, 1536-1536.	1.4	3
50	Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms. <i>Blood</i> , 2015, 126, 3232-3232.	1.4	1
51	Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis. <i>Blood</i> , 2015, 126, 4340-4340.	1.4	0
52	Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma. <i>Current Opinion in Hematology</i> , 2013, 20, 509-514.	2.5	7
53	Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. <i>British Journal of Haematology</i> , 2008, 143, 395-403.	2.5	97
54	Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. <i>Journal of Autoimmunity</i> , 2008, 30, 172-179.	6.5	58

#	ARTICLE	IF	CITATIONS
55	Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies. Expert Opinion on Biological Therapy, 2008, 8, 161-179.	3.1	17
56	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 211-217.	1.6	186